Generic Name and Formulations:
Dorzolamide HCl 2%; oph soln; contains benzalkonium chloride.
Merck & Co., Inc.
Indications for TRUSOPT:
Open-angle glaucoma. Ocular hypertension.
Adults and Children:
1 drop 3 times daily.
Hepatic impairment. Severe renal impairment (CrCl <30mL/min): not recommended. Discontinue if ocular effects (eg, conjunctivitis, lid reactions) occur. Soft contact lenses. Pregnancy (Cat.C). Nursing mothers: not recommended.
Carbonic anhydrase inhibitor (sulfonamide).
Concomitant oral carbonic anhydrase inhibitors: not recommended. May inhibit renal excretion of basic drugs and promote excretion of acidic drugs. May increase salicylate toxicity (acidosis).
Burning, stinging, bitter taste, punctate keratitis, ocular allergic reaction, blurred vision, tearing, dryness, photophobia; possible sulfa-like systemic effects.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline